Endo International PLC (NASDAQ:ENDP) (TSE:ENL) had its price target reduced by analysts at BMO Capital Markets from $11.00 to $10.00 in a report released on Friday. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 44.30% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the company. Mizuho reiterated a “buy” rating and set a $19.00 target price on shares of Endo International PLC in a report on Thursday, August 10th. Deutsche Bank AG set a $13.00 price objective on Endo International PLC and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine upgraded Endo International PLC from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research upgraded Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a report on Wednesday, October 11th. Finally, Morgan Stanley decreased their price objective on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $11.67.
Shares of Endo International PLC (ENDP) traded up $0.84 during trading hours on Friday, reaching $6.93. The company’s stock had a trading volume of 12,136,900 shares, compared to its average volume of 7,342,927. The firm has a market cap of $1,550.00, a PE ratio of 1.43 and a beta of 0.53. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $18.63.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International PLC’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.01 EPS. equities analysts anticipate that Endo International PLC will post 3.54 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://ledgergazette.com/2017/11/13/bmo-capital-markets-lowers-endo-international-plc-endp-price-target-to-10-00.html.
In other Endo International PLC news, CFO Blaise Coleman acquired 6,500 shares of Endo International PLC stock in a transaction dated Tuesday, August 15th. The stock was acquired at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the transaction, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.
A number of large investors have recently made changes to their positions in ENDP. James Investment Research Inc. bought a new stake in Endo International PLC during the second quarter worth approximately $113,000. Blair William & Co. IL bought a new stake in Endo International PLC during the second quarter worth approximately $126,000. LMR Partners LLP bought a new stake in Endo International PLC during the third quarter worth approximately $148,000. Point View Wealth Management Inc. raised its holdings in Endo International PLC by 16.6% during the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after purchasing an additional 1,900 shares in the last quarter. Finally, Riverhead Capital Management LLC raised its holdings in Endo International PLC by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares in the last quarter. 90.50% of the stock is currently owned by hedge funds and other institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.